Drug
Mobocertinib
Mobocertinib: highest development phase Phase 1, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mobocertinib NCT03807778 | Phase 1 | Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow Mobocertinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.